Jun 1, 2004
Citations
0
Influential Citations
0
Citations
Journal
Expert Opinion on Therapeutic Patents
Abstract
ASTRAZENECA AB: Henriksson K, Munck AR. 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP-12. Novel 2,5-dioxoimidazolidin-4-yl acetamide derivatives are claimed for the treatment of matrix metalloproteinase (MMP)-12 mediated disorders, especially asthma or chronic obstructive pulmonary disease (COPD). Ten compounds were found to inhibit recombinant human MMP-12 in vitro with median inhibitory concentration (IC50) values of 0.004 – 0.032 μM. A total of 100 compounds are exemplified by syntheses with characterisation data and > 100 are specifically claimed. WO04020415 (11/03/2004) 87 pages.